Pandemic COVID-19: Current status and challenges of antiviral therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pandemic COVID-19: Current status and challenges of antiviral therapies

Published:2020-12 Issue:4 Volume:7 Page:502-519
ISSN:2352-3042
Container-title:Genes & Diseases
language:en
Short-container-title:Genes & Diseases

Author:

Chan Winglam,He Betsy,Wang Xiong,He Ming-Liang

Funder

The Science Technology and Innovation Committee of Shenzhen Municipality

National Science Foundation of China

City University of Hong Kong

Publisher

Elsevier BV

Subject

Cell Biology,Genetics (clinical),Molecular Biology,Biochemistry

Reference148 articles.

1. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2;Nat Microb,2020

2. COVID-19 Coronavirus Pandemic,2020

3. Revisiting the Dangers of the Coronavirus in the Ophthalmology Practice;Seah,2020

4. The spike protein of SARS-CoV—a target for vaccine and therapeutic development;Du;Nat Rev Microbiol,2009

5. Molecular immune pathogenesis and diagnosis of COVID-19;Li;J Pharmaceut Anal,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection;Signal Transduction and Targeted Therapy;2023-06-07

2. Drug target of natural products and COVID-19: how far has science progressed?;Annals of Medicine & Surgery;2023-04-19

3. A comprehensive review on disposition kinetics and dosage of oral administration of Andrographis paniculata, an alternative herbal medicine, in co-treatment of coronavirus disease;Frontiers in Pharmacology;2022-08-19

4. BEE VENOM AND ITS BIOLOGICAL EFFECTS;Current Perspectives on Medicinal and Aromatic Plants (CUPMAP);2022-06-28

5. Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells;Antimicrobial Agents and Chemotherapy;2022-01-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3